Development of a Bioluminescent Cell-Based Assay to ... - Promega

More documents

Recommendations

Info

ADCC Reporter Bioassay can measure potency of antibody drugs in different systems Suspension or adherent target cells can be used Rituximab (anti-CD20) CD20 + B cell lines (suspension) as target cells (plated directly from suspension) Confidential and Proprietary. Not for Further Disclosure. Trastuzumab (anti-Her-2) Her2 + breast cancer cell lines (adherent) as target cells (plated 16-18hr prior) 18
ADCC Reporter Bioassay is stability-indicating for Fc effector function Rituximab Confidential and Proprietary. Not for Further Disclosure. Tositumomab EC50 = 5.77ng/ml EC50 = 31.0ng/ml Activity of heat-treated antibody drugs Trastuzumab
Page 1 and 2: Development of a Bioluminescent Cel
Page 3 and 4: Signaling pathways activated in eff
Page 5 and 6: Protocol 1. Reference or test antib
Page 7 and 8: FcgRIIIa antibody blocking of ADCC
Page 9 and 10: Bioassay development: Optimizing Ef
Page 11 and 12: Bioassay development: Evaluating cl
Page 13 and 14: Target cells can also be frozen, th
Page 15 and 16: ADCC Reporter Bioassay using frozen
Page 17: Precision, accuracy and linearity o
Page 21 and 22: Additional target cell option: Raji
Page 23 and 24: iological activity of therapeutic a
Page 25 and 26: Planned ADCC Reporter Bioassay kit
Page 27: For more information Confidential a

Development of a Bioluminescent Cell-Based Assay to ... - Promega

Create successful ePaper yourself

Delete template?

Save as template?